U.S. flag

An official website of the United States government

Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 2 books (10 items)

  • The following term was not found in Books: PLIN1-related.
  • Quoted phrase not found.
  • See the search details.
1.
Metreleptin (Myalepta): CADTH Reimbursement Recommendation: Indication: As an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients: with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above with confirmed familial partial LD (PL) or acquired PL (Barraquer-Simons syndrome), in adults and children 12 years of age and above with persistent significant metabolic disease for whom standard treatments have failed to achieve adequate metabolic control [Internet].

Metreleptin (Myalepta): CADTH Reimbursement Recommendation: Indication: As an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients: with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above with confirmed familial partial LD (PL) or acquired PL (Barraquer-Simons syndrome), in adults and children 12 years of age and above with persistent significant metabolic disease for whom standard treatments have failed to achieve adequate metabolic control [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.

Table of Contents

2.
CADTH Reimbursement Reviews and Recommendations.

CADTH Reimbursement Reviews and Recommendations.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.

Table of Contents

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...